The Adult Hematology Clinic at the University of Michigan Rogel Cancer Center cares for patients with benign and malignant disorders of the blood and lymphatic organs, and is committed to providing patients the very best care and treatment.
The University of Michigan Rogel Cancer Center provides comprehensive cancer care, cutting-edge treatment, plus new therapies and clinical trials through our multidisciplinary cancer clinics.
Hereditary Hemorrhagic Telangiectasia (HHT) is a genetic disorder that affects about one in 5,000 people and commonly causes nosebleeds, with more frequent nosebleeds typically starting after about age 12. Patients with HHT have a tendency to form blood vessels that are abnormal, fragile, and bleed more easily. Michigan Medicine has a multidisciplinary team of physicians to treat HHT, including specialists in otolaryngology (for nosebleeds), pulmonary diseases, interventional radiology, gastroenterology, neurosurgery, liver diseases, cardiology, heart failure, dermatology, radiation oncology, hematology-oncology and associated pediatric subspecialties.
There are many different specialists who treat patients with HHT. Many patients will eventually see two or more types of specialists, especially later in adulthood. Specialists who treat HHT include otolaryngologists (ear, nose & throat doctors), interventional radiologists (to treat AVMs), hematologists (to help manage anemia), and more.
